company background image
4AB logo

AbbVie DB:4AB Stock Report

Last Price

€165.00

Market Cap

€291.5b

7D

0.3%

1Y

12.3%

Updated

25 Mar, 2024

Data

Company Financials +

AbbVie Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$165.00
52 Week HighUS$167.30
52 Week LowUS$119.00
Beta0.56
1 Month Change-0.24%
3 Month Change19.74%
1 Year Change12.29%
3 Year Change82.32%
5 Year Change130.22%
Change since IPO553.21%

Recent News & Updates

Recent updates

Shareholder Returns

4ABDE BiotechsDE Market
7D0.3%3.3%1.6%
1Y12.3%35.8%6.4%

Return vs Industry: 4AB underperformed the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: 4AB exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is 4AB's price volatile compared to industry and market?
4AB volatility
4AB Average Weekly Movement2.8%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4AB has not had significant price volatility in the past 3 months.

Volatility Over Time: 4AB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201250,000Rick Gonzalezhttps://www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
4AB fundamental statistics
Market cap€291.52b
Earnings (TTM)€4.45b
Revenue (TTM)€50.11b

65.6x

P/E Ratio

5.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4AB income statement (TTM)
RevenueUS$54.32b
Cost of RevenueUS$16.73b
Gross ProfitUS$37.59b
Other ExpensesUS$32.77b
EarningsUS$4.82b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.72
Gross Margin69.21%
Net Profit Margin8.87%
Debt/Equity Ratio573.6%

How did 4AB perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

220%

Payout Ratio

Does 4AB pay a reliable dividends?

See 4AB dividend history and benchmarks
When do you need to buy 4AB by to receive an upcoming dividend?
AbbVie dividend dates
Ex Dividend DateApr 12 2024
Dividend Pay DateMay 15 2024
Days until Ex dividend17 days
Days until Dividend pay date50 days

Does 4AB pay a reliable dividends?

See 4AB dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.